Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Elson

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1994
Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trialP J Loehrer, P Elson, R Dreicer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 30, 1999
Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12J Ulchaker, J Panuto, P Rayman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 3, 2010
Temsirolimus in VEGF-refractory metastatic renal cell carcinomaM J MacKenzie, B I Rini, P Elson, et al.
Journal of Cancer Research and Clinical Oncology|October 16, 2001
GM-CSF safety and effects in the management of advanced/refractory multiple myeloma patients: a phase I trialM A Hussein, K Sandstrom, P Elson, et al.
Clinical Genitourinary Cancer|December 17, 2013
Clinical outcome of stereotactic radiosurgery for central nervous system metastases from renal cell carcinomaD J Seastone, P Elson, J A Garcia, et al.
The Journal of Urology|November 1, 1990
Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. The Eastern Cooperative Oncology GroupD L Trump, P Elson, S Madajewicz, et al.
Cancer Biotherapy|January 1, 1993
The impact of interleukin-2 on survival in renal cancer: a multivariate analysisM Jones, T Philip, P Palmer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 23, 2000
Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: clinical and biologic effectsT Olencki, J Finke, R Tubbs, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 27, 2007
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenibI Tamaskar, R Bukowski, P Elson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosisS A Vaziri, L M Krumroy, P Elson, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1994
Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trialP J Loehrer, P Elson, R Dreicer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 30, 1999
Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12J Ulchaker, J Panuto, P Rayman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 3, 2010
Temsirolimus in VEGF-refractory metastatic renal cell carcinomaM J MacKenzie, B I Rini, P Elson, et al.
Journal of Cancer Research and Clinical Oncology|October 16, 2001
GM-CSF safety and effects in the management of advanced/refractory multiple myeloma patients: a phase I trialM A Hussein, K Sandstrom, P Elson, et al.
Clinical Genitourinary Cancer|December 17, 2013
Clinical outcome of stereotactic radiosurgery for central nervous system metastases from renal cell carcinomaD J Seastone, P Elson, J A Garcia, et al.
The Journal of Urology|November 1, 1990
Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. The Eastern Cooperative Oncology GroupD L Trump, P Elson, S Madajewicz, et al.
Cancer Biotherapy|January 1, 1993
The impact of interleukin-2 on survival in renal cancer: a multivariate analysisM Jones, T Philip, P Palmer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 23, 2000
Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: clinical and biologic effectsT Olencki, J Finke, R Tubbs, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 27, 2007
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenibI Tamaskar, R Bukowski, P Elson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosisS A Vaziri, L M Krumroy, P Elson, et al.
Pageof 6